QABY is a biotech start-up encompassing novel antibodies, innovative assays, unique biomarkers and long-standing know-how tackling neurodegenerative diseases. Our technologies would enable early detection of neurodegenerative diseases, assessing treatment response and monitoring disease progression thus accelerating the reach for therapeutic solutions and improving the quality of life for patients living with such devastating diseases. Our key activities include:
1) Research & development (R&D); Developing new research tools and assays and discovering new disease targets based on scientific discoveries,
2) Providing a service; QABY technologies have been selected by several pharma companies as part of their clinical trials,
3) Antibodies & kits; selling antibodies and kits directly to end users.